Live Breaking News & Updates on Medalliance Chairman

Stay updated with breaking news from Medalliance chairman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

MedAlliance Announces Enrollment of over 1,660 Patients in Landmark

MedAlliance has announced enrollment of over 1,660 patients in its ground breaking SELUTION DeNovo coronary randomized ....

Switzerland General , United States , France General , Languedoc Roussillon , Richard Kenyon , Christian Spaulding , Paris Cite University , Cat Tm Cell Adherent Technology , Cardiology Department , European Hospital Georges , Assistance Publique Hopitaux De Paris , Safety Monitoring Board , Medalliance Chairman , Cell Adherent Technology , Middle East ,

Over 1,000 patients enrolled in Landmark SELUTION DeNovo Study

Geneva [Switzerland], March 15 (ANI/PRNewswire): MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now a third of the way towards the target of 3,326 patients. SELUTION DeNovo compares the treatment strategy using a novel sirolimus drug-eluting balloon [DEB SELUTION], versus a limus drug-eluting stent [DES]. SELUTION DeNovo is the largest DEB study ever initiated, involving up to 70 participating sites across 15 countries. Patients are randomized before any vessel preparation to reflect current medical practice and to reduce bias. The objectives of the study are to demonstrate non-inferiority at both one and five years, and superiority for target vessel failure (TVF) at five years. This study is designed to change medical practice, as the majority of de novo coronary lesions are currently treated with a permanent metallic stent. SELUTION SLR consists of an angioplasty balloon coated with MicroRes ....

France General , Switzerland General , United States , Richard Kenyon , Georges Pompidou , Christian Spaulding , Cardiology Department , Cell Adherent Technology , Paris Cite University , European Hospital Georges Pompidou , Assistance Publique Hopitaux De Paris , Medalliance Chairman , Middle East , Geneva Switzerland , Arch 15 Ani Prnewswire Medalliance Has Announced Enrollment Of Over 1 , 000 Patients In Its Ground Breaking Selution Denovo Coronary Randomized Study Recruitment Is Nowa Third Of The Way Towards Target 3 , 326 Patients Selution Denovo Compares The Treatment Strategy Usinga Novel Sirolimus Drug Eluting Balloon Deb , Ersusa Limus Drug Eluting Stent Des Selution Denovo Is The Largest Deb Study Ever Initiated , Nvolving Up To 70 Participating Sites Across 15 Countries Patients Are Randomized Before Any Vessel Preparation Reflect Current Medical Practice And Reduce Bias The Objectives Of Study Demonstrate Non Inferiority At Both One Five Years , Nd Superiority For Target Vessel Failure Tvf At Five Years This Study Is Designed To Change Medical Practice , S The Majority Of De Novo Coronary Lesions Are Currently Treated Witha Permanent Metallic Stent Selution Slr Consists An Angioplasty Balloon Coated With Microreservoirs Containinga Mixture Biodegradable Polymer And Anti Restenotic Drug Sirolimus These Provide Controlled Sustained Release For Over 90 Days , Imilar Toa Des , Ut Without Leaving Behinda Metal Scaffold , Hich Has Been Associated Witha Complication Rate Of 2 Annually Quot This Isa Major Milestone For The Selution Denovo Trial , S It Is Now The Largest Deb Study Ever Conducted , Uot Said Co Principal Investigator Professor Christian Spaulding ,

Over 1,000 Patients Enrolled in Landmark SELUTION DeNovo Study

Over 1,000 Patients Enrolled in Landmark SELUTION DeNovo Study
thaipr.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thaipr.net Daily Mail and Mail on Sunday newspapers.

United States , France General , Switzerland General , Richard Kenyon , Prnewswire Infoquest , Christian Spaulding , Georges Pompidou , Cardiology Department , Cell Adherent Technology , European Hospital Georges Pompidou , Paris Cit , Medalliance Chairman , Middle East ,

Over 1,000 Patients Enrolled in Landmark SELUTION DeNovo Study

This will complement the substantial experience that the company has gained with the SELUTION DeNovo trial in Europe.MedAlliances unique DEB technology involves MicroReservoirs which contain a mixture of biodegradable polymer intermixed with the anti-restenotic drug sirolimus applied as a coating on the surface of an angioplasty balloon. ....

United States , France General , Switzerland General , Richard Kenyon , Christian Spaulding , Georges Pompidou , Cardiology Department , Cell Adherent Technology , European Hospital Georges Pompidou , Paris Cit , Medalliance Chairman , Middle East , Jeffreyb Jump , European Hospital Georges Pompidou , Co Principal Investigator , Medalliance Medalliance , E Mark Approval , Cell Adherent Technology , Aris Cit 233 University , Elution Denovo ,

Over 1,000 patients enrolled in Landmark SELUTION DeNovo Study

Geneva [Switzerland], March 15 (ANI/PRNewswire): MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo coronary randomized study ....

United States , France General , Switzerland General , Christian Spaulding , Georges Pompidou , Cardiology Department , Paris Cite University , Cell Adherent Technology , European Hospital Georges Pompidou , Assistance Publique Hopitaux De Paris , Medalliance Chairman , Middle East , Ews India ,